Department of Clinical Immunology, Great Ormond Street Hospital National Health Service Trust, London, UK.
Blood. 2011 Mar 17;117(11):3243-6. doi: 10.1182/blood-2010-08-300384. Epub 2011 Jan 27.
Severe combined immunodeficiency (SCID) carries a poor prognosis without definitive treatment by hematopoietic stem cell transplantation. The outcome for transplantation varies and is dependent on donor status and the condition of the child at the time of transplantation. Diagnosis at birth may allow for better protection of SCID babies from infection and improve transplantation outcome. In this comparative study conducted at the 2 designated SCID transplantation centers in the United Kingdom, we show that SCID babies diagnosed at birth because of a positive family history have a significantly improved outcome compared with the first presenting family member. The overall improved survival of more than 90% is related to a reduced rate of infection and significantly improved transplantation outcome irrespective of donor choice, conditioning regimen used, and underlying genetic diagnosis. Neonatal screening for SCID would significantly improve the outcome in this otherwise potentially devastating condition.
严重联合免疫缺陷(SCID)如果不通过造血干细胞移植进行明确治疗,预后很差。移植的结果因供体状况和移植时患儿的情况而异。出生时的诊断可以更好地保护 SCID 婴儿免受感染,并改善移植结果。在英国 2 家指定的 SCID 移植中心进行的这项比较研究中,我们表明,由于阳性家族史而在出生时诊断出的 SCID 婴儿的结果明显优于首次出现的家族成员。总体生存率提高到 90%以上,这与感染率降低以及无论供体选择、使用的调理方案和潜在遗传诊断如何,移植结果都显著改善有关。新生儿 SCID 筛查将显著改善这种潜在的毁灭性疾病的结果。